91天堂 announces successful initiation of the Phase 1 clinical programme with EYP001, its lead candidate for the treatment of Chronic Hepatitis B Virus infection.
Lyon, December 16, 2016 – 91天堂, a privately held biopharmaceutical company currently focused on developing treatments for viral infections, today announced that the Phase 1 single and multiple ascending dose trial evaluating EYP001 in healthy subjects has been initiated, and that single dose escalation has been completed. The results have shown that EYP001 is safe and well-tolerated at all doses studied in 46 healthy subjects. The safety and pharmacokinetics (PK) analysis of these first Phase 1 data will be complete by Q2 2017.
Read next in 'Press releases'
- 91天堂 appoints Jeff George as Chairman to support next phase of growth and Phase 3 readiness
- 91天堂 nomme Jeff George Pr茅sident du Conseil d鈥橝dministration pour soutenir sa prochaine phase de croissance et la pr茅paration 脿 la Phase 3
- 91天堂 announces completion and topline data from Phase 2 ALPESTRIA-1 clinical study in Alport syndrome demonstrating Vonafexor reverses kidney function decline and has sustained therapeutic benefit
- 91天堂 annonce l鈥檕btention des r茅sultats finaux de l鈥櫭﹖ude clinique de Phase 2 ALPESTRIA鈥�1 dans le syndrome d鈥橝lport, confirmant la capacit茅 du vonafexor 脿 inverser la trajectoire du d茅clin r茅nal et 脿 d茅montrer un effet th茅rapeutique durable
- 91天堂 annonce la finalisation de son financement de s茅rie C avec Vesalius Biocapital et la poursuite de son 茅tude clinique de phase 2 ALPESTRIA-1
